Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
This is an On-demand recording from June 2021
China NMPA overarching policy “Regulation on the Supervision and Administration of Medical Devices”, or Order 739, will be effective on June 1st, 2021. This new policy from China State Council has 8 chapters and 107 articles covering the complete product life cycle in an effort to create a more efficient and less burdensome approval process. For overseas medical device/IVD companies, it means faster China market access. In this webcast, we will review the key highlights of this new policy and the implications for overseas companies in premarket submission clinical and technical requirements, innovation focus, MAH and post market changes.
Basic: Content is introductory in nature and requires no requisite knowledge or experience to grasp concepts and related exercises. Basic educational activities are meant to establish a foundation of knowledge and/or competence that will be expanded upon in practice or in higher level activities.
Grace Fu Palma has more than 20 years of medical technology and diagnostic industry experience. She is the CEO of China Med Device, providing turnkey solutions for western medical device/IVD/CDx products companies entering China. The company has processed more than 1,000 China National Medical Products Administration (NMPA) certificates, and accelerated more than 250 companies’ success. A seasoned bilingual and bicultural MedTech executive, Fu Palma has held a variety of marketing, operational and strategic development management positions at both large multinationals and startup companies. She specializes in China NMPA and commercialization services. She grew up in Beijing, and has a bachelor’s degree from Peking University, China, and an MBA from Yale University.
Yan Sheng grew up in China and has years of experience working in the life science industry in both the US and China, and has more than eight years of experience as a project manager at a CRO. She has experience with drug development companies in both the US and China such as Alfa Chemistry Inc. in the US, and Hangzhou Huadong Medicine Group Co. Ltd. in China. Sheng has six years of experience in the academic field working with cutting edge technologies in both chemistry and microbiology, and has extensive research expertise in natural products chemistry, molecular biology and microbiology, genetic manipulation, protein expression and purification, and in vitro enzymatic reactions. Sheng has been published in a number of academic journals and has a PhD in pharmaceutical sciences.